There is a continuing pervasive public perception that the FDA has been ineffective in protecting the public. Recent news events in foods, drugs, and devices seem to support this perception. The "tougher" FDA is determined to change that perception. Industry must be prepared to adapt, and recognize that such adaptation will actually work to their long-term benefit. This webinar will discuss and evaluate the effects that this call for change has on a company and its change control policies and systems. Control and review of device changes are a major requirement in determining when to file a new 510(k). Change can be beneficial, but is often the cause of new and even worse problems than those the change was designed to eliminate. It can be the root cause of a major problem, cGMP "entropy". Proper change control is hard to achieve but required to resolve any underlying compliance issues or product problems that are increasingly seen by regulatory agencies and consumers worldwide. To meet these regulatory challenges and remain competitive, companies need to continually reevaluate their change control system and its impact on all areas of a company's cGMP activities.
5 Dec 2012 @ 10:00 am
5 Dec 2012 @ 11:30 am
Duration: 1 hours, 30 minutes
Timezone: GMT -8:00
Organised by GlobalCompliancePanel (deactivated)